National collection to incorporate biological drugs, traditional Chinese medicine insulin lead stocks should fall!

On July 17th, the National Health Insurance Administration announced that it intends to include biological products (including insulin) and traditional Chinese medicines in centralized procurement.
although the symposium did not disclose much, but the industry for when to carry out, and which varieties will be included in the collection and so on are very concerned.
based on the previous band purchase progress, this symposium or just warm-up, the industry is expected to biological products and traditional Chinese medicine belt procurement or in early 2021.
at present, the national collection is basically mainly chemical drugs, the third batch is expected to be carried out in the second half of the year, if six months after the collection to expand to biological drugs, traditional Chinese medicine, the relevant drug market is expected to usher in a big storm ... Insulin, biosimilar drugs selected in the probability of large combined with the characteristics of biological products, according to the local collection has been carried out, the industry generally believes that insulin, biosimilar drugs will be the focus area of collection.
insulin leading stocks have been "sound" fell in January this year, Wuhan in the country to start the first insulin band procurement bargain, 7 groups of insulin total agreed procurement volume of 1.7 million, involving Glyce Pharmaceuticals, Novo Nordisk, Lilly, Sanofi, Tonghua Dongbao, Federal Pharmaceuticals and other 9 enterprises.
the size of The market size of Wuhan insulin collection is about 130 million yuan, but only 0.7% of the national market.
According to the results of the April election, a total of 21 different manufacturers of different dosage forms shortlisted, foreign enterprises in the selection of up to 15 kinds, mainly Novo Nordisk, Lilly, accounting for nearly 60%.
affected by the outbreak, Wuhan insulin band procurement bid price has not been announced, has not yet landed.
but the industry guesses that Wuhan belt procurement, insulin price reduction is only a small single digit.
on the one hand, the bargaining power of the municipal collection is still limited, and the city-level collection has the tendency to be stopped;
the current national collection is mainly chemical drugs-based, the evaluation of varieties to carry out collection, can achieve generic drug substitution of primary research.
if insulin is to be collected nationwide, the overall price will be reduced, which is a test for domestic and foreign enterprises.
"the sound of the wind, the grass and wood are soldiers."
the news that insulin products are about to be collected, capital markets seem to have begun to respond.
domestic insulin leading enterprises Tonghua Dongbao and Ganli Pharmaceuticals shares fell sharply, at the end of June on the Shanghai Stock Exchange main board listed Gan Li Pharmaceutical, two consecutive board, this morning's morning is a halt, the midday close down 8.02%, the market value from the highest break 100 billion to 85.5 billion yuan;
domestic biosimilar sororsubstitution substitution and accelerated biosimilar sisathing refers to therapeutic biological products that are similar in quality, safety and efficacy to approved reference drugs.
previously due to the lack of competition and other factors in the country, the original research biopharmaceuticals, although after the patent period, but also in China enjoy the "super-national" treatment.
most of the domestic market for biopharmaceuticals is occupied by foreign-funded enterprises, with higher unit prices.
with the medical insurance negotiations, bevalzumab, Adamu monotonica and other biologically similar drugs appear, biological drugs in China began to decline, drug accessibility also increased simultaneously.
's Frost Sullivan report notes that China's biosimilar drug market will experience explosive growth in the coming years, with the market size reaching 58.9 billion yuan by 2030.
now the national collection is aimed at this area, with more and more biosimilardrugs approved for sale, the future of biosimilar drugs may be widely occupied the domestic biopharmaceutical market.
at present, Adamu monoid, Beval-Zhu mono-anti two products have more than 3 enterprises production, Bai Otai and Haizheng Pharmaceuticals Adamu monoanti-biosimilars have been listed at the end of last year, Zhengda Tianqing, Cinda Bio and Fuhong Hanxuan have submitted the listing application;
in addition, including rituximab, qutodzumab and other products also have a lot of domestic enterprise layout, a number of domestic biological similar drugs approved after the acquisition of the volume of the chances will be greater.
chinese medicine collection, is it a blessing or a curse? In recent years, Traditional Chinese medicine has been affected by policies such as "limited prescriptions", revision of instructions, key monitoring, and restrictions on payment of health insurance, and overall sales growth has continued to slow, with negative growth in 2019.
on the other side, provincial and municipal collections also have the figure of traditional Chinese medicine.
In June this year, Jinhua City, Zhejiang Province officially issued the second batch of drug-belt procurement announcement, a total of 180 Chinese medicine, involving Yunnan white medicine, pediatric stoic anti-yellowing hot particles, Pudi blue anti-inflammatory oral liquid and other best-selling products;
in such a situation, especially for some of the focus on monitoring of traditional Chinese medicine, the national collection of good or short is not good to say.
Chinese medicine to carry out collection, which varieties will bear the brunt? Southwest Securities analysis said that the hospital-end sales of large, effective, in the health insurance catalog of oral varieties into the collection of the list of higher likelihood.
the current non-health insurance, partial consumption, as well as the main retail channels of traditional Chinese medicine into the probability is low, the early sales of more affected Chinese medicine injections into the catalog is less likely.
, unlike chemical drugs, Traditional Chinese medicine lacks data on safety and efficacy, and the rules are more complex.
if Chinese traditional medicine to carry out a wide range of collection, the industry has been calling for the market of traditional Chinese medicine after evaluation policy or will accelerate the arrival.
traditional Chinese medicine collection is more complex, follow-up may require the introduction of relevant standards.
in the short term blood products, vaccines, etc. or do not consider different from chemical sandals and traditional Chinese medicine, the development of biological products in China is relatively late.
some biological products have a higher quality level, research and development is difficult, the number of production enterprises is relatively small, market competition is relatively moderate, while the overall production capacity of biological products in China is low, difficult to expand rapidly in the short term, many enterprises are difficult to ensure the stability of supply, but also to carry out a certain degree of difficulty in the purchase of the belt.
Southwest Securities pointed out that in the short term, blood products, vaccines and other participation is less likely.
Huajin Securities also said that the vaccine products in a class of vaccine slower prices and the National Health and Care Commission's tender and procurement, the second type of seedlings is not currently included in the scope of medical insurance payment, and enterprise capacity supply is limited, the possibility of procurement of the amount is not high.
blood products due to raw material problems, the possibility of inclusion in the collection of short-term is also low.
January this year, Henan Puyang has led the procurement of growth hormone products, but due to the growth hormone medical insurance payment is limited, and the dosage form is more abundant, it is expected that the market share is not high powder needle may be the amount of procurement, self-funded water needles, long-term water needles and other short-term collection possibilities are low.
in addition, the symposium only mentioned traditional Chinese medicine, not chinese medicine tablets and formula particles.
.